Randomized Placebo-controlled Study on the Effects of Antibiotic-induced Gut MicrobiomE Disruption on the Innate Immune Response Following Cardiac Surgery
Overview
- Phase
- Not Applicable
- Intervention
- Vancomycin Oral
- Conditions
- Systemic Inflammatory Response Syndrome
- Sponsor
- Radboud University Medical Center
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Between group differences in Area Under the Curve (AUC) of the time-concentration curve of interleukin (IL)-6 plasma concentrations.
- Last Updated
- 5 years ago
Overview
Brief Summary
In this randomized, double-blind, placebo-controlled study, the investigators will assess whether preoperative disruption of the gut microbiota by a course of broad spectrum antibiotics will attenuate the postoperative systemic inflammatory response after on-pump cardiac surgery
Detailed Description
During cardiac surgery, the use of cardiopulmonary bypass and extracorporeal circulation, operative trauma, and ischemia-reperfusion injury can induce a profound systemic innate immune response. This response contributes to postoperative morbidity and mortality, as increased proinflammatory cytokine levels are associated with several postoperative complications. Commensal microbiota in the gut can modulate systemic immune responses. The investigators hypothesize that reduction of systemic immune activation by disruption of the microbiome may be beneficial in patients undergoing cardiac surgery. The objective of this trial is to assess the anti-inflammatory effects of disruption of the intestinal microbiota with broad-spectrum antibiotics in patients with systemic inflammation following cardiac surgery and to assess the effects on clinical outcomes in these patients. To this end, subjects will be randomized into one of two treatment arms and will receive either active treatment or a placebo during the seven days prior to surgery. Active treatment consists of a seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day. Placebo treatment is randomly allocated in a double blind fashion in a 1:1 proportion to the active treatment. Stool samples will be obtained prior to and directly after study treatment to assess the effects on the richness and diversity of the gut microbiota. During and after surgery, plasma levels of circulating cytokines will be measured to assess the effects of microbiota disruption on the inflammatory response.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years
- •Scheduled for elective on-pump cardiac surgery.
- •Written informed consent to participate in this trial prior to any study-mandated procedure
Exclusion Criteria
- •Use of any antibiotic or antifungal therapies within 30 days prior to surgery
- •History of inflammatory bowel disease
- •History of bowel resection and / or short bowel syndrome
- •Pre-operative creatinine clearance \< 50 ml/min
- •Severe hepatic impairment
- •Immune compromised
- •Solid organ transplantation
- •Known HIV
- •Pregnancy
- •Use of immunosuppressive drugs
Arms & Interventions
Active group
A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
Intervention: Vancomycin Oral
Active group
A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
Intervention: Metronidazole Oral
Active group
A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
Intervention: Ciprofloxacin Pill
Active group
A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
Intervention: Fluconazole Oral Product
Control group
A preoperative seven day course of placebo, consisting of pills and capsules identical in appearance and number to the active group
Intervention: Placebos
Outcomes
Primary Outcomes
Between group differences in Area Under the Curve (AUC) of the time-concentration curve of interleukin (IL)-6 plasma concentrations.
Time Frame: During surgery and up to 24 hours after surgery
Blood samples will be obtained at predefined time points during and after surgery to assess plasma levels (in pg/mL) of circulating inflammatory mediators. To assess between group differences, the AUC of the time-concentration curve (expressed in arbitrary units) of each inflammatory mediator will be calculated.
Secondary Outcomes
- Between group differences in AUC of the time-concentration curve of other inflammatory mediators.(During surgery and up to 24 hours after surgery)